Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Peter C. Black, H.A.D.M. Ashab et al.|European Urology|2017Cited by 793
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Ashish M. Kamat et al.|The Lancet Oncology|2021Cited by 532
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Marek Babjuk et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for CystoscopyKim E.M. van Kessel, Ellen C. Zwarthoff, Willemien Beukers et al.|The Journal of Urology|2016Cited by 154